Semaglutide Shrinks Muscles but Leaves Strength Intact

Here’s a puzzle that’s keeping researchers awake at night: People taking semaglutide, the weight-loss wonder drug behind Ozempic and Wegovy, are losing muscle mass along with fat. But what if smaller muscles aren’t necessarily weaker muscles?

A study published August 5 in Cell Metabolism throws a wrench into our assumptions about what muscle loss really means. When researchers gave semaglutide to mice, something unexpected happened. Yes, the animals’ skeletal muscles shrank, but they didn’t lose an ounce of their strength.

The Mystery of Disappearing Muscle

The concern isn’t theoretical. In the landmark STEP-1 clinical trial, patients taking semaglutide shed an average of 15.3 kilograms. Nearly half of that weight came from lean tissue (muscle, organs, bones) not just fat. That ratio broke the typical “quarter fat-free mass rule” that doctors expect with conventional weight loss.

For older adults already battling age-related muscle loss, or anyone worried about frailty, this raised red flags. Lose too much muscle, and simple tasks like climbing stairs or carrying groceries become monumental challenges.

“Despite the great interest in this topic, few studies have sufficiently contextualized the loss of lean tissue induced by semaglutide,” the authors write.

When Size Doesn’t Equal Strength

The research team decided to dig deeper with a mouse study designed to answer the burning questions: Does semaglutide specifically target skeletal muscle? Is this just obesity-related muscle gain reversing itself? Most importantly, do shrinking muscles mean weaker muscles?

What they discovered challenges everything we thought we knew about muscle loss. The mice on semaglutide did lose skeletal muscle mass, just as the clinical data suggested. But when researchers tested how much force those smaller muscles could generate, the numbers stayed rock-solid.

Think of it like this: imagine a sports car that gets smaller but maintains the same horsepower. The package shrinks, but the performance doesn’t budge.

The Plot Thickens

This strength-preserving muscle loss isn’t entirely unprecedented. Cancer patients experiencing severe muscle wasting known as cachexia, sometimes show similar patterns. But seeing it with a blockbuster obesity drug adds layers of complexity to an already intricate story.

The implications ripple outward in unexpected directions:

• Not all muscle loss is created equal: Some of the muscle gained during obesity might reflect the body’s response to carrying extra weight, not healthy muscle growth
• Function trumps size: If strength remains intact, the cosmetic concerns about muscle shrinkage may overshadow the functional reality
• Age matters: Older adults might experience this phenomenon differently than younger, healthier populations

The Bigger Picture

The study’s authors urge caution in interpreting body composition changes during pharmacological weight loss. We’re essentially watching a massive real-world experiment unfold, with millions of people taking these medications based on limited long-term data about muscle function.

The researchers emphasize that losing some types of lean mass during weight loss might actually signal a return to healthier baselines, rather than functional decline. It’s the difference between losing essential muscle and shedding excess tissue that served no beneficial purpose.

But here’s what we still don’t know: Will these findings from mice translate to humans? How do these changes affect daily activities over months and years? What happens to people who are already at risk for frailty?

Rewriting the Playbook

As GLP-1 receptor agonists like semaglutide become household names, this research suggests we need better ways to measure success than stepping on a scale. Muscle function tests, mobility assessments, and quality-of-life measures may prove more revealing than weight loss alone.

The message emerging from this work is nuanced: semaglutide may indeed shrink your muscles, but that doesn’t automatically translate to weakness. Whether that distinction matters for long-term health and function remains the million-dollar question.

For now, the scorecard reads: smaller muscles, same strength, bigger questions.

Journal: Cell Metabolism DOI: 10.1016/j.cmet.2025.07.004